Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20720672 | 0.79 | ACHE (0.51) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| SCHEMBL9039716 | 0.77 | ACHE (0.51) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| SCHEMBL28984958 | 0.75 | CYP1A2 (0.65) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| SCHEMBL20720783 | 0.72 | CYP1A2 (0.58) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| SCHEMBL5083430 | 0.72 | ACHE (0.66) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| SCHEMBL9042096 | 0.72 | CYP1A2 (0.60) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| SCHEMBL3807927 | 0.71 | CYP1A2 (0.72) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| SCHEMBL9738138 | 0.70 | CYP1A2 (0.58) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| SCHEMBL7935382 | 0.70 | CYP1A2 (0.58) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| SCHEMBL9041102 | 0.70 | CYP1A2 (0.58) | ACHECYP1A2CYP2C9TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | ACHE 3056/4885CYP1A2 4681/4885CYP2C9 4519/4885 |
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | ACHE 3056/4885CYP1A2 4681/4885CYP2C9 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.